The civic record
Read. Follow. Verify.Oklahoma restricts insurers from disadvantaging FDA-approved non-opioid pain treatments on preferred drug lists
Last action · April 1, 2025: Second Reading referred to Health and Human Services Committee then to Appropriations CommitteeSponsor: Andy Fugate
Track this bill to get notified when it advances a stage. One tap to stop, anytime.
What This Bill Proposed
State employee group insurance plans and insurers must ensure that FDA-approved non-opioid pain treatments are not disadvantaged or discouraged regarding coverage relative to opioid or narcotic drugs on s, effective November 1, 2025.
Who It Would Have Affected
Groups the bill's text would have affected, as described in the record. Being affected is not a position for or against it.
state employees
insurers
Insurers offering state employee group insurance plans must structure their preferred drug lists to ensure non-opioid pain treatments are not disadvantaged relative to opioids.
health care prescribers
Health care prescribers may prescribe non-opioid treatments under group insurance plans subject to the new preferred drug list parity requirements.
Key Facts
You don't have to trust us. Each fact below is taken straight from the official document - click any one to see the exact passage, highlighted in the original.
Frequently Asked Questions
Does this bill ban the use of opioid medications on preferred drug lists?
What else do you want to know?
News Coverage
Follow the record
Votes, people, money & the original sourceWhere This Stands
This bill did not become law - Died at adjournment · passed the House · in Senate committee.
Procedural history
16 actions- Apr 1, 2025SenateCommitteeSecond Reading referred to Health and Human Services Committee then to Appropriations Committee
- Mar 4, 2025SenateIntroducedFirst Reading
- Mar 4, 2025HouseEngrossed, signed, to Senate
- Mar 3, 2025HouseCommitteeReferred for engrossment
- Mar 3, 2025HouseFloorThird Reading, Measure passed: Ayes: 90 Nays: 7
- Mar 3, 2025HouseTitle stricken
Show 10 earlier actions
- Mar 3, 2025HouseAmended
- Mar 3, 2025HouseCoauthored by Representative(s) Fugate
- Mar 3, 2025HouseGeneral Order
- Feb 26, 2025HouseFloorCR; Do Pass, amended by committee substitute Health and Human Services Oversight Committee
- Feb 5, 2025HouseAuthored by Senator Rosino (principal Senate author)
- Feb 5, 2025HouseFloorPolicy recommendation to the Health and Human Services Oversight committee; Do Pass Public Health
- Feb 4, 2025HouseCommitteeReferred to Public Health
- Feb 4, 2025HouseCommitteeSecond Reading referred to Health and Human Services Oversight
- Feb 3, 2025HouseAuthored by Representative West (Josh)
- Feb 3, 2025HouseIntroducedFirst Reading
Version history
Only one version on file - nothing to compare yet. As later stages (committee substitute, engrossed, enrolled) are captured, the redline appears here.
View official text →Lobbying Activity
No state lobbying filings in our records match this bill. Federal lobbying reports (LDA) cover Congress, so they are not listed on state bills.
Full breakdown
Who this bill affects and the strongest case for and against it, written only from the bill’s own text.
Sponsors
Connected Entities
Sources
www.oklegislature.gov
Analysis Score
0–100- Significance20Lowered because this bill did not pass (its text scored 60)
- Controversy20Intensity of disagreement among stakeholders
- Entertainment5Compellingness for a non-policy-wonk reader
- Buzz30Current news / social attention level
Publisher tools